Usana Health Sciences Analyst Ratings
Usana Health Sciences Analyst Ratings
While ratings are subjective and will change, the latest Usana Health Sciences (USNA) rating was a maintained with a price target of $57.00 to $49.00. The current price Usana Health Sciences (USNA) is trading at is $56.99, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/27/2022 | -14.02% | DA Davidson | $57 → $49 | Maintains | Neutral |
| 07/28/2022 | 0.02% | DA Davidson | $58 → $57 | Maintains | Neutral |
| 07/12/2022 | 1.77% | DA Davidson | $76 → $58 | Maintains | Neutral |
| 07/07/2022 | -7% | Jefferies | $78 → $53 | Downgrades | Hold → Underperform |
| 04/27/2022 | 33.36% | DA Davidson | $86 → $76 | Maintains | Neutral |
| 04/14/2022 | 50.9% | DA Davidson | → $86 | Initiates Coverage On | → Neutral |
| 02/10/2021 | 121.09% | Roth Capital | $107 → $126 | Maintains | Buy |
| 12/17/2020 | 87.75% | Roth Capital | → $107 | Initiates Coverage On | → Buy |
| 08/22/2019 | 14.06% | Jefferies | → $65 | Initiates Coverage On | → Hold |
| 07/03/2019 | 22.83% | Sidoti & Co. | $108 → $70 | Downgrades | Buy → Neutral |
| 04/16/2019 | — | Tigress Financial | Initiates Coverage On | → Buy | |
| 04/23/2018 | — | Pivotal Research | Downgrades | Buy → Hold | |
| 01/24/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 10/27/2022 | -14.02% | DA Davidson | 57 美元 → 49 美元 | 维护 | 中立 |
| 07/28/2022 | 0.02% | DA Davidson | 58 美元 → 57 美元 | 维护 | 中立 |
| 2022 年 12 月 7 日 | 1.77% | DA Davidson | 76 美元 → 58 美元 | 维护 | 中立 |
| 07/07/2022 | -7% | 杰富瑞集团 | 78 美元 → 53 美元 | 降级 | 持有 → 表现不佳 |
| 04/27/2022 | 33.36% | DA Davidson | 86 美元 → 76 美元 | 维护 | 中立 |
| 2022 年 4 月 14 日 | 50.9% | DA Davidson | → 86 美元 | 启动覆盖范围开启 | → 中立 |
| 2021 年 10 月 2 日 | 121.09% | 罗斯资本 | 107 美元 → 126 美元 | 维护 | 买 |
| 2020 年 12 月 17 日 | 87.75% | 罗斯资本 | → 107 美元 | 启动覆盖范围开启 | → 购买 |
| 08/22/2019 | 14.06% | 杰富瑞集团 | → 65 美元 | 启动覆盖范围开启 | → 按住 |
| 07/03/2019 | 22.83% | Sidoti & Co. | 108 美元 → 70 美元 | 降级 | 买入 → 中性 |
| 04/16/2019 | — | 泰格雷斯金融 | 启动覆盖范围开启 | → 购买 | |
| 04/23/2018 | — | 关键研究 | 降级 | 买入 → 持有 | |
| 2018 年 1 月 24 日 | — | Sidoti & Co. | 降级 | 买入 → 中性 |
Usana Health Sciences Questions & Answers
Usana 健康科学问题与解答
The latest price target for Usana Health Sciences (NYSE: USNA) was reported by DA Davidson on October 27, 2022. The analyst firm set a price target for $49.00 expecting USNA to fall to within 12 months (a possible -14.02% downside). 6 analyst firms have reported ratings in the last year.
戴维森于2022年10月27日公布了Usana Health Sciences（纽约证券交易所代码：USNA）的最新目标股价。该分析公司将目标股价定为49.00美元，预计USNA将在12个月内跌至12个月内（可能下跌-14.02％）。去年有6家分析公司公布了评级。
The latest analyst rating for Usana Health Sciences (NYSE: USNA) was provided by DA Davidson, and Usana Health Sciences maintained their neutral rating.
Usana Health Sciences（纽约证券交易所代码：USNA）的最新分析师评级由DA Davidson提供，Usana Health Sciences维持中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Usana Health Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Usana Health Sciences was filed on October 27, 2022 so you should expect the next rating to be made available sometime around October 27, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Usana Health Sciences的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Usana Health Sciences的最新评级是在2022年10月27日发布的，因此您应该预计下一个评级将在2023年10月27日左右公布。
While ratings are subjective and will change, the latest Usana Health Sciences (USNA) rating was a maintained with a price target of $57.00 to $49.00. The current price Usana Health Sciences (USNA) is trading at is $56.99, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Usana Health Sciences（USNA）评级维持不变，目标股价为57.00美元至49.00美元。Usana Health Sciences（USNA）目前的交易价格为56.99美元，超出了分析师的预期区间。
